CCRA® — Certified Clinical Research Associate — Questions and Answers

Question 1: Good Manufacturing Practice (GMP) requirements for investigational products are primarily intended to ensure:

Compatibility with commercial packaging standards
Cost-effective production of clinical supplies
Rapid manufacturing to meet enrollment timelines
Product quality, identity, purity, and potency for subject safety and reliable trial results (Correct answer)

Correct answer: Product quality, identity, purity, and potency for subject safety and reliable trial results

GMP for investigational products (21 CFR Part 211 in the US) ensures that manufacturing processes produce consistent, safe, and accurately labeled product that supports both subject safety and data integrity.

Question 2: In clinical data management, 'edit checks' are used to:

Grant data entry permissions to site coordinators
Validate data entries against predefined rules to detect out-of-range values, missing data, or logical inconsistencies (Correct answer)
Correct CRF data automatically without site input
Send regulatory submissions automatically

Correct answer: Validate data entries against predefined rules to detect out-of-range values, missing data, or logical inconsistencies

Edit checks (or validation rules) are programmed into EDC systems to flag data that is missing, illogical, or outside expected ranges, prompting review or generating queries.

Question 3: According to ICH E6(R2), what is meant by 'essential documents'?

Documents that individually and collectively permit evaluation of the conduct of a trial and the quality of the data produced (Correct answer)
Only the signed informed consent forms from all enrolled subjects
The sponsor's internal SOPs for clinical monitoring
CRFs submitted to the FDA for regulatory review

Correct answer: Documents that individually and collectively permit evaluation of the conduct of a trial and the quality of the data produced

Essential documents are those that individually and collectively allow evaluation of the trial's conduct and data quality, and they form the Trial Master File.

Question 4: What is the purpose of a 'double-blind dummy' (matching placebo or active control) in a clinical trial?

To satisfy FDA labeling requirements
To provide a backup supply of investigational product
To reduce manufacturing costs
To maintain blinding by ensuring all treatment arms have identical appearance, so neither subjects nor site staff can distinguish active from placebo (Correct answer)

Correct answer: To maintain blinding by ensuring all treatment arms have identical appearance, so neither subjects nor site staff can distinguish active from placebo

Matching placebos or dummy controls are formulated to be identical in appearance, taste, and texture to the active product, preserving blinding integrity throughout the trial.

Question 5: A study subject becomes pregnant during a clinical trial of a teratogenic investigational compound. After being taken off study drug, what additional obligation typically applies?

The subject should be referred to a different clinical trial
The sponsor has no further obligations once the drug is stopped
The pregnancy must be reported as an SAE and followed to outcome (Correct answer)
The site must immediately terminate the subject's participation with no follow-up

Correct answer: The pregnancy must be reported as an SAE and followed to outcome

Pregnancies in trials of potentially teratogenic drugs are typically reportable SAEs, and pregnancy outcomes (including neonatal outcomes) must be tracked and reported.

Question 6: The MedDRA coding system is used in clinical trials to:

Assign billing codes for insurance reimbursement
Code laboratory values for statistical analysis
Classify investigational products by pharmacological class
Standardize medical terminology for adverse event classification and regulatory reporting (Correct answer)

Correct answer: Standardize medical terminology for adverse event classification and regulatory reporting

MedDRA (Medical Dictionary for Regulatory Activities) is the internationally recognized medical terminology system used to classify adverse events and medical conditions in regulatory submissions.

Question 7: An investigator at a US site is found to have a significant financial interest in the sponsor company. According to 21 CFR Part 54, the sponsor must:

Disclose the financial interest to the FDA in the marketing application (Correct answer)
Immediately remove the investigator from the trial
Require the investigator to divest all financial interests before enrollment begins
Obtain IRB approval to allow the investigator to continue

Correct answer: Disclose the financial interest to the FDA in the marketing application

21 CFR Part 54 requires sponsors to disclose investigators' significant financial interests to the FDA as part of the marketing application so regulators can assess potential bias.

Question 8: Which GCP principle states that the rights, safety, and well-being of trial subjects are the most important considerations?

Ethical principle of primacy of subject protection (Correct answer)
Scientific validity principle
Data integrity principle
Principle of equipoise

Correct answer: Ethical principle of primacy of subject protection

ICH E6(R2) principle 2.3 explicitly states that the rights, safety, and well-being of trial subjects must prevail over the interests of science and society.

Question 9: What is the PRIMARY purpose of a Site Qualification Visit (SQV) conducted by a CRA?

To train site staff on the study protocol procedures
To collect completed Case Report Forms from previous studies
To assess the site's capability and resources to conduct the clinical trial (Correct answer)
To deliver investigational product to the site pharmacy

Correct answer: To assess the site's capability and resources to conduct the clinical trial

The SQV evaluates whether the site has adequate facilities, staff expertise, patient population, and regulatory infrastructure to successfully conduct the trial.

Question 10: A site investigator wants to add a new co-investigator to the trial team mid-study. What GCP-required steps must be completed before the new co-investigator can perform any study activities?

The sponsor must issue a formal protocol amendment
Verbal approval from the CRA is sufficient
IRB approval, CV submission, GCP training documentation, and addition to the delegation log (Correct answer)
Only signature of a new CTA amendment is needed

Correct answer: IRB approval, CV submission, GCP training documentation, and addition to the delegation log

New study personnel must have updated CVs on file, documented GCP training, IRB acknowledgment per site SOP, and be formally delegated responsibilities on the delegation of authority log.

Question 11: When investigational product is returned from a site for destruction, the CRA must confirm:

The returned IP is tested for potency before destruction
The site has purchased replacement supplies
All returned IP is properly labeled, logged, and accompanied by documentation confirming quantities and condition (Correct answer)
The subjects who used the IP have signed an additional consent

Correct answer: All returned IP is properly labeled, logged, and accompanied by documentation confirming quantities and condition

Returned IP must be documented with quantities matching records, properly labeled, and accompanied by return authorization documentation; this ensures full accountability and proper destruction.

Question 12: Which document type serves as the definitive guide for CRAs on how to perform site visits for a specific trial?

Clinical Study Report
Investigator Brochure
Site Initiation Checklist
Monitoring Plan (Correct answer)

Correct answer: Monitoring Plan

The Monitoring Plan specifies the monitoring strategy, methodology, responsibilities, and procedures to be followed during trial monitoring visits.

Question 13: Which of the following is a key difference between a CRA (Clinical Research Associate) and a CRC (Clinical Research Coordinator)?

A CRA and a CRC perform identical functions in clinical research
A CRA works at the clinical site; a CRC works for the regulatory agency
A CRA approves the protocol; a CRC writes the informed consent form
A CRA is typically employed by the sponsor or CRO and monitors sites; a CRC works at the investigator site and supports trial conduct (Correct answer)

Correct answer: A CRA is typically employed by the sponsor or CRO and monitors sites; a CRC works at the investigator site and supports trial conduct

CRAs are sponsor or CRO employees who monitor site compliance, while CRCs are site staff who assist investigators in day-to-day trial operations.

Question 14: A CRA should have which qualification as a minimum to independently monitor clinical trials per ICH-GCP?

A law degree specializing in FDA regulations
A PhD in pharmacology
10 years of nursing experience
Scientific or clinical training and experience enabling proper assessment of medical, pharmaceutical, and data aspects of the trial (Correct answer)

Correct answer: Scientific or clinical training and experience enabling proper assessment of medical, pharmaceutical, and data aspects of the trial

ICH E6(R2) section 5.18.2 states monitors must have scientific and/or clinical training and experience to evaluate the medical, pharmaceutical, and procedural aspects of a clinical trial.

Question 15: From 1932 until 1972, the Tuskegee Syphilis Study was conducted.

No
Yes (Correct answer)

Correct answer: Yes

Yes, the infamous Tuskegee Syphilis Study was indeed conducted from 1932 until 1972 by the U.S. Public Health Service. This study observed the natural progression of untreated syphilis in African American men without their informed consent or offering them available treatment. It stands as a profound example of unethical research, leading to significant reforms in human subject protection and research ethics.

Question 16: Which ICH E6(R2) addendum concept introduced the idea of proportionate monitoring based on risk?

Elimination of the Trial Master File requirement
Risk-based monitoring (RBM) focusing oversight on critical data and processes (Correct answer)
Central monitoring replacing all on-site visits
Source data verification of 100% of CRF entries

Correct answer: Risk-based monitoring (RBM) focusing oversight on critical data and processes

ICH E6(R2) introduced risk-based monitoring, directing CRA resources toward critical processes and data that have the greatest impact on subject safety and data integrity.

Question 17: A 'protocol-defined SAE exemption' means:

The sponsor can waive all SAE reporting for a trial
IRB approval is not required for exempt SAEs
Subjects are not informed about exempt SAEs
Certain SAEs anticipated by the disease or procedure do not require expedited reporting to the sponsor if specified in the protocol (Correct answer)

Correct answer: Certain SAEs anticipated by the disease or procedure do not require expedited reporting to the sponsor if specified in the protocol

Protocols may pre-specify SAEs that are expected outcomes of the underlying disease or procedure, exempting them from the standard immediate reporting requirement to reduce reporting burden.

Question 18: At a Site Initiation Visit, the CRA discovers the site's designated pharmacy lacks proper temperature-controlled storage for the investigational product. What should the CRA do?

Report the finding to the FDA directly without informing the sponsor
Immediately halt the site initiation and require corrective action before enrollment begins (Correct answer)
Instruct the site to store the product at room temperature temporarily
Allow enrollment to begin but document the finding in the monitoring report

Correct answer: Immediately halt the site initiation and require corrective action before enrollment begins

Inadequate storage conditions violate GCP and could compromise product integrity and subject safety; enrollment must not begin until compliant storage is confirmed.

Question 19: What is the primary purpose of a Form FDA 1572 (Statement of Investigator)?

To authorize IRB approval
To report adverse events to the sponsor
To document the investigator's commitments and qualifications to conduct the trial per FDA regulations (Correct answer)
To request drug shipment from the manufacturer

Correct answer: To document the investigator's commitments and qualifications to conduct the trial per FDA regulations

FDA Form 1572 is a legal agreement in which the investigator commits to conducting the trial per the protocol, GCP, and applicable regulations, and lists key personnel and IRB information.

Question 20: A site coordinator asks a CRA if she can enter data into the CRF on behalf of the investigator to save time. What should the CRA advise?

Site staff may enter data if authorized and trained, but the investigator must review and sign off on all entries per protocol (Correct answer)
No, only the principal investigator may ever enter any CRF data
Yes, if the investigator verbally approves later
Yes, as long as the CRA counter-signs the entries

Correct answer: Site staff may enter data if authorized and trained, but the investigator must review and sign off on all entries per protocol

Sub-investigators and coordinators may enter CRF data if authorized by the investigator and documented on the site's delegation log, with the investigator retaining oversight responsibility.

Question 21: Risk-Based Monitoring (RBM) focuses monitoring resources primarily on:

Sites with the highest enrollment numbers
Identified critical data and processes with the greatest patient risk potential (Correct answer)
Regulatory submission timelines
Sites closest geographically to the sponsor

Correct answer: Identified critical data and processes with the greatest patient risk potential

RBM, as endorsed by ICH E6(R2) and FDA guidance, prioritizes monitoring efforts based on identified risks to subject safety and data integrity rather than routine 100% source data verification.

Question 22: A Monitoring Visit Report (MVR) must be completed and submitted to the sponsor within the timeframe specified in the monitoring plan primarily to:

Satisfy enrollment quotas
Archive IRB correspondence
Document visit findings and ensure timely follow-up on issues identified (Correct answer)
Bill the site for monitoring costs

Correct answer: Document visit findings and ensure timely follow-up on issues identified

The MVR documents all findings, actions taken, and required follow-up items to ensure issues are tracked to resolution and the sponsor maintains oversight of site compliance.

Question 23: When a protocol amendment requires IRB approval before implementation, who is responsible for ensuring the amendment is approved prior to implementation at the site?

The Sponsor (Correct answer)
The IRB Chair
The Principal Investigator
The CRO

Correct answer: The Sponsor

The sponsor is responsible for submitting protocol amendments to the FDA and ensuring IRB approval is in place before the amended protocol is implemented at investigational sites.

Question 24: Which ICH-GCP section outlines the sponsor's responsibilities regarding monitoring?

Section 8 (Essential Documents)
Section 4 (Investigator)
Section 5 (Sponsor) (Correct answer)
Section 6 (Protocol)

Correct answer: Section 5 (Sponsor)

ICH E6(R2) Section 5 covers sponsor responsibilities, including establishing a monitoring system, selecting qualified monitors, and defining monitoring scope and frequency.

Question 25: Under ICH-GCP E6(R2), the sponsor's audit differs from monitoring in that audits are:

Systematic independent evaluations to assess trial conduct (Correct answer)
Conducted by the CRA during routine site visits
Performed only at the FDA's request
Focused solely on financial compliance

Correct answer: Systematic independent evaluations to assess trial conduct

Audits under ICH E6(R2) are systematic, independent examinations of trial-related activities and documents to evaluate whether the trial is conducted per the protocol, SOPs, GCP, and regulations.

Question 26: During a monitoring visit, the CRA finds that the investigator site file (ISF) is missing the latest protocol amendment signed by the PI. What action should the CRA take?

File the document on behalf of the site without notifying the sponsor
Ignore the issue if the PI verbally confirms awareness of the amendment
Document the missing document as a finding and request that the site obtain and file it promptly (Correct answer)
Immediately terminate the site from the study

Correct answer: Document the missing document as a finding and request that the site obtain and file it promptly

A missing signed protocol amendment in the ISF is a documentation deficiency that must be documented in the monitoring report and remediated by the site.

Question 27: Which document is considered the primary source for verifying that informed consent was obtained before any study procedures were performed?

The signed and dated informed consent form (Correct answer)
The protocol synopsis
The investigator's brochure
The subject's enrollment log

Correct answer: The signed and dated informed consent form

The signed and dated informed consent form is the primary document confirming that consent was obtained prior to study participation.

Question 28: During site close-out, the CRA confirms that all essential documents are filed, IP is reconciled, and staff is debriefed. Which document officially marks the end of a site's participation in a trial?

Final Data Transfer Agreement
Site Close-Out Letter (Correct answer)
End-of-Study Notification to IRB
Final Monitoring Visit Report

Correct answer: Site Close-Out Letter

The Site Close-Out Letter is the formal communication from the sponsor to the investigator confirming the site's participation in the study has ended.

Question 29: When a site in the US enrolls a subject without a valid IRB approval, the CRA should first:

Instruct the site to re-consent the subject
Report directly to the FDA without sponsor notification
Notify the sponsor and document the protocol deviation (Correct answer)
Immediately terminate the site

Correct answer: Notify the sponsor and document the protocol deviation

The CRA must notify the sponsor and document the deviation per the monitoring plan; the sponsor then determines escalation steps including possible regulatory reporting.

Question 30: Dosage and safety (Find out how the medicine affects human metabolism and pharmacology).

Primary purpose of a phase 1 study? (Correct answer)
Non-refundable start-up fees:
Type of Trial Comparisons?
ICH HARMONISED TRIPARTITE GUIDELINE E11

Correct answer: Primary purpose of a phase 1 study?

The primary purpose of a Phase 1 clinical study is to evaluate the safety of a new drug, determine a safe dosage range, and identify potential side effects. These studies also investigate the drug's pharmacokinetics (how the body processes the drug) and pharmacodynamics (how the drug affects the body) in humans. This initial phase helps establish the drug's basic profile in humans.

Question 31: Which ICH E6(R2) principle states that clinical trial information should be recorded, handled, and stored in a way that allows its accurate reporting, interpretation, and verification?

Subject confidentiality
Investigator qualification
Data integrity (Correct answer)
Risk-based monitoring

Correct answer: Data integrity

ICH E6(R2) emphasizes that all clinical trial data must be handled and stored to allow accurate reporting, interpretation, and verification.

Question 32: Under FDA regulations, which document defines the sponsor's delegation of trial-related duties to a CRO?

Monitoring Plan
Protocol Amendment
Written Transfer of Obligations (Correct answer)
Clinical Trial Agreement

Correct answer: Written Transfer of Obligations

21 CFR Part 312 requires a written transfer of obligations document when a sponsor transfers any trial duties to a CRO.

Question 33: What is the primary purpose of the Declaration of Helsinki?

To set standards for statistical analysis in clinical trials
To provide ethical principles for medical research involving human subjects (Correct answer)
To establish FDA regulatory requirements for drug approval
To define Good Manufacturing Practice (GMP) requirements

Correct answer: To provide ethical principles for medical research involving human subjects

The Declaration of Helsinki is a foundational ethical document developed by the World Medical Association to guide researchers conducting studies involving human participants.

Question 34: What is a doctor's alternate name in the clinical field?

Sponsor
Randomization
Monitor
Investigator (Correct answer)

Correct answer: Investigator

In the context of clinical research, a doctor who is responsible for conducting a clinical trial at a specific site is referred to as an 'Investigator,' or more specifically, a 'Principal Investigator' (PI) if they are the lead physician. This term highlights their role in overseeing the study and ensuring patient safety and data integrity.

Question 35: What is the maximum time frame the FDA allows for a sponsor to submit an IND safety report for an unexpected fatal or life-threatening SUSAR?

15 calendar days
7 calendar days (Correct answer)
30 calendar days
24 hours

Correct answer: 7 calendar days

Under 21 CFR 312.32, unexpected fatal or life-threatening suspected unexpected serious adverse reactions must be reported to the FDA within 7 calendar days.

Question 36: What is the purpose of a Pre-Study Site Qualification Visit (SQV)?

To evaluate whether the site and investigator have the capabilities, resources, and patient population to conduct the trial (Correct answer)
To collect final data and close out the study at the site
To train site staff on the protocol after IRB approval
To deliver investigational product to the site for the first time

Correct answer: To evaluate whether the site and investigator have the capabilities, resources, and patient population to conduct the trial

An SQV assesses the site's facilities, staff qualifications, patient access, and overall feasibility before committing to site selection.

Question 37: A 'comparator product' in a clinical trial refers to:

A backup supply of investigational product
A generic version of the investigational product
An approved product (or placebo) used as a reference against which the investigational product is evaluated (Correct answer)
A placebo without active ingredients

Correct answer: An approved product (or placebo) used as a reference against which the investigational product is evaluated

The comparator is an approved medicinal product or placebo used in a controlled trial to compare against the investigational product's safety and efficacy profile.

Question 38: What is a 'For-Cause Audit' in clinical research?

An audit performed solely for financial compliance
A scheduled routine audit performed annually
A required pre-submission audit before NDA filing
An unplanned audit triggered by signals of potential fraud, GCP violations, or data integrity concerns (Correct answer)

Correct answer: An unplanned audit triggered by signals of potential fraud, GCP violations, or data integrity concerns

A for-cause audit is triggered by specific concerns such as whistleblower reports, unusual data patterns, or serious GCP breaches, and is conducted to investigate the issue in depth.

Question 39: When investigational product is transferred between two investigational sites, which step is MOST critical?

Allowing the CRA to transport the product during a monitoring visit
Obtaining sponsor approval and ensuring complete chain of custody documentation with temperature monitoring during transfer (Correct answer)
Confirming both sites are in the same city
Ensuring the receiving site has a lower temperature during transit

Correct answer: Obtaining sponsor approval and ensuring complete chain of custody documentation with temperature monitoring during transfer

Site-to-site IP transfers require sponsor authorization and complete documentation of the chain of custody, including temperature conditions during transit, to maintain product integrity and accountability.

Question 40: During a pre-study site evaluation visit, the CRA assesses several factors. Which finding would most likely lead the sponsor to REJECT a site?

The site has conducted only two prior clinical trials
The site's pharmacy stores investigational product in a separate area
The investigator's delegation log is not yet prepared
The site lacks sufficient staff and patient population to meet enrollment targets (Correct answer)

Correct answer: The site lacks sufficient staff and patient population to meet enrollment targets

Insufficient patient population or staffing capacity directly threatens the feasibility of completing the trial and is grounds for not selecting a site.

Question 41: What is a Data Safety Monitoring Board (DSMB) and its primary function in clinical trials?

An independent committee that periodically reviews accumulating safety data to protect subject welfare and trial integrity (Correct answer)
A group of site staff who manage local safety reporting
A regulatory body that approves IND applications
A sponsor department responsible for AE database entry

Correct answer: An independent committee that periodically reviews accumulating safety data to protect subject welfare and trial integrity

A DSMB (or IDMC) is an independent group of experts that reviews unblinded safety and efficacy data at interim timepoints to recommend trial continuation, modification, or termination.

Question 42: Site staff may not open or break the blind of randomization codes except:

After enrollment of the first 10 subjects for interim safety review
When the CRA requests unblinding during a monitoring visit
When medically necessary for subject safety (e.g., medical emergency) following the pre-defined emergency unblinding procedure (Correct answer)
When a subject requests to know their treatment assignment

Correct answer: When medically necessary for subject safety (e.g., medical emergency) following the pre-defined emergency unblinding procedure

Emergency unblinding is permitted only when knowledge of treatment is medically necessary to protect the subject, and must follow a documented procedure with notification to the sponsor.

Question 43: In clinical trials, 'outcome' for an adverse event typically refers to which of the following classifications?

Related, possibly related, unrelated, unknown
Expected, unexpected, serious, non-serious
Mild, moderate, severe, life-threatening, fatal
Recovered/resolved, recovering/resolving, not recovered/not resolved, recovered with sequelae, fatal, unknown (Correct answer)

Correct answer: Recovered/resolved, recovering/resolving, not recovered/not resolved, recovered with sequelae, fatal, unknown

Standard AE outcome categories describe the resolution status of the event: recovered, recovering, not recovered, recovered with sequelae, fatal, or unknown.

Question 44: What is the name of the document that the site must sign and date before making a QV appointment?

A CDA (Correct answer)
REMOTE VISIT
A PLACEBO
MONITORING REPORT

Correct answer: A CDA

Before a Qualification Visit (QV) or any initial site contact involving confidential study information, a Confidential Disclosure Agreement (CDA), also known as a Non-Disclosure Agreement (NDA), must be signed. This legal document ensures that proprietary information shared by the sponsor or CRO with the site during the evaluation process remains confidential.

Question 45: What information must appear on investigational product labels per GCP and regulatory requirements?

Commercial product name and manufacturer address
Subject name, date of birth, and insurance information
Trial number, protocol ID, subject/dose information, storage conditions, sponsor contact, and the statement 'For Clinical Trial Use Only' (Correct answer)
Only the product name and lot number

Correct answer: Trial number, protocol ID, subject/dose information, storage conditions, sponsor contact, and the statement 'For Clinical Trial Use Only'

GCP IP labels must include the clinical trial identification, dosing information, storage requirements, sponsor or manufacturer contact, and the mandatory statement that the product is for investigational use only.

Question 46: Conflict of interest is a risk factor for scientific misconduct in clinical research investigations.

No
Yes (Correct answer)

Correct answer: Yes

Yes, a conflict of interest is a significant risk factor for scientific misconduct in clinical research investigations. When researchers, sponsors, or institutions have financial or other personal interests that could improperly influence the design, conduct, or reporting of a study, it can compromise the integrity of the research and the safety of participants. Transparency and strict management of conflicts of interest are crucial to maintaining research ethics and credibility.

Question 47: What is the minimum required retention period for clinical trial essential documents under FDA regulations?

2 years after the last subject's last visit
2 years after a marketing application is approved, or 2 years after the IND is terminated if no application is filed (Correct answer)
10 years after study completion
5 years after database lock

Correct answer: 2 years after a marketing application is approved, or 2 years after the IND is terminated if no application is filed

Under 21 CFR 312.62, investigational records must be retained for 2 years following the date a marketing application is approved, or 2 years after IND discontinuation if no application is submitted.

Question 48: What is the purpose of investigational product (IP) accountability at a clinical trial site?

To ensure accurate records of all IP received, dispensed, returned, and destroyed to verify subject compliance and prevent misuse (Correct answer)
To track IP shipment transit times
To monitor competitive product use by subjects
To calculate the sponsor's manufacturing costs

Correct answer: To ensure accurate records of all IP received, dispensed, returned, and destroyed to verify subject compliance and prevent misuse

IP accountability requires maintaining records showing the disposition of every unit of investigational product to confirm it was used only for trial purposes and that subjects received the correct doses.

Question 49: When an investigator is taking part in a fresh protocol that has been added to the IND<br> When a fresh researcher is brought into the research

Blister packages (where each drug is placed in an individual plastic dome on a card) enhance compliance in three ways:
If a research pharmacy is not available, investigational products can be stored in other areas as long as the following requirements are met
In the guidance, the FDA noted that there are two instances when it is necessary for an investigator to complete and sign a new Form FDA 1572: (Correct answer)
Once an IND application becomes effective, a sponsor-investigator is required to submit the following reports/updates to the FDA.

Correct answer: In the guidance, the FDA noted that there are two instances when it is necessary for an investigator to complete and sign a new Form FDA 1572:

Form FDA 1572 is a contract between the investigator and the FDA, outlining the investigator's commitments to conduct the study according to the protocol and regulations. The FDA guidance specifies that a new Form 1572 must be completed and signed when a new investigator is added to the research or when an existing investigator participates in a new protocol that has been added to the Investigational New Drug (IND) application.

Question 50: Under FDA 21 CFR Part 312, the sponsor must notify the FDA of an IND safety report (IND Safety Report) within how many calendar days for unexpected fatal or life-threatening SUSARs?

30 calendar days
7 calendar days (Correct answer)
45 calendar days
15 calendar days

Correct answer: 7 calendar days

Fatal or life-threatening unexpected serious adverse reactions must be reported to the FDA within 7 calendar days of the sponsor's first knowledge.

Question 51: A CRA discovers that a site has been using an expired version of the informed consent form. What is the MOST immediate action?

Terminate the investigator immediately
Submit a serious breach report to the IRB without sponsor involvement
Document the finding and require re-consent using the current IRB-approved form (Correct answer)
Halt all trial procedures at the site

Correct answer: Document the finding and require re-consent using the current IRB-approved form

The CRA must document the deviation and work with the site to re-consent affected subjects using the current approved form, while reporting to the sponsor per the monitoring plan.

Question 52: The IRB is not required under the FDA standards to make sure that children's consent is secured.

Phase I Clinical Trials
Formulary Drug
Investigational Drug (Correct answer)
Established Drug

Correct answer: Investigational Drug

The statement provided in the question is factually incorrect; IRBs are mandated by FDA regulations to ensure appropriate protections for children in clinical trials, which includes obtaining parental permission and, when appropriate, the child's assent. This stringent oversight is particularly crucial for studies involving investigational drugs, as these are new treatments whose safety and efficacy in pediatric populations need careful evaluation. Therefore, the context of 'Investigational Drug' is where the IRB's role in safeguarding children's rights and welfare is paramount.

Question 53: What action should a CRA take if a site refuses to correct a major protocol deviation identified during a monitoring visit?

Escalate the issue to the sponsor's management and document the refusal in the monitoring report (Correct answer)
Personally correct the deviation by altering the site's records
Contact the FDA directly to report the site without notifying the sponsor
Accept the site's position and close out the visit without further action

Correct answer: Escalate the issue to the sponsor's management and document the refusal in the monitoring report

When a site refuses corrective action, the CRA must document the refusal and escalate to sponsor management, who may involve regulatory authorities or terminate the site.

Question 54: What is the primary objective of a Site Initiation Visit (SIV)?

To audit financial records
To resolve outstanding data queries
To train site staff and confirm readiness to enroll subjects (Correct answer)
To collect final data and close the site

Correct answer: To train site staff and confirm readiness to enroll subjects

The SIV ensures that site staff are adequately trained on the protocol, procedures, and GCP requirements, and that all essential documents and supplies are in place before enrollment begins.

Question 55: What does 'query resolution' involve in clinical data management?

Resolving IRB approval queries from site staff
Identifying, clarifying, and correcting data discrepancies or missing data in CRFs through a formal communication process (Correct answer)
Resolving financial payment disputes between sponsor and sites
Answering protocol questions from investigators

Correct answer: Identifying, clarifying, and correcting data discrepancies or missing data in CRFs through a formal communication process

Query resolution is the process by which data managers or CRAs flag data issues in the CRF/EDC, sites investigate and correct the data, and the resolution is documented with an explanation.

Question 56: Which practice best ensures blinding integrity during data management activities?

Unblinding all data before database lock for quality review
Allowing site coordinators to access treatment assignment codes in the EDC
Sharing treatment assignments with data managers for context
Limiting access to randomization codes to only those who need them for safety monitoring, with all others remaining blinded (Correct answer)

Correct answer: Limiting access to randomization codes to only those who need them for safety monitoring, with all others remaining blinded

Maintaining blinding integrity requires strict access controls to randomization codes, ensuring that only authorized personnel (e.g., DSMB members, emergency unblinding team) can access treatment assignments.

Question 57: Is it necessary to obtain approval from ________ before starting a clinical research study?

None of the above
Regulators and ethics committees (Correct answer)
Sponsor
Regulator

Correct answer: Regulators and ethics committees

Before commencing a clinical research study, it is absolutely necessary to obtain approval from both regulatory authorities and ethics committees. Regulatory bodies (e.g., FDA) ensure compliance with national and international laws and guidelines. Ethics committees (e.g., IRBs/IECs) are independent bodies that safeguard the rights, safety, and well-being of study participants, ensuring the study is ethically sound. This dual approval is mandatory for legal and ethical conduct.

Question 58: Under ICH E6(R2), what is the minimum content required in a monitoring visit report?

Date of visit, site visited, CRA name, findings, deviations, and follow-up actions (Correct answer)
Enrollment numbers only
List of all subjects enrolled and their randomization codes
Protocol version and IRB approval number

Correct answer: Date of visit, site visited, CRA name, findings, deviations, and follow-up actions

ICH E6(R2) requires monitoring reports to capture the visit date, site, monitor identity, findings, deviations, and any required follow-up actions.

Question 59: During IP reconciliation at a monitoring visit, the CRA discovers more units were dispensed than accounted for in subject dosing records. The FIRST action is to:

Assume it is a counting error and move on
Report the site to the FDA immediately
Investigate the discrepancy with site staff and document findings; notify the sponsor if unresolved (Correct answer)
Destroy the excess IP immediately

Correct answer: Investigate the discrepancy with site staff and document findings; notify the sponsor if unresolved

IP discrepancies must be investigated with site staff to identify the cause; if unexplained, the sponsor must be notified, and depending on severity, regulatory reporting or a for-cause audit may be required.

Question 60: In a clinical trial using an Electronic Data Capture (EDC) system, audit trails serve to:

Replace the paper CRF process entirely
Record all data entries, changes, deletions, and the identity of the person making changes with timestamps (Correct answer)
Automatically correct data entry errors
Eliminate the need for source document verification

Correct answer: Record all data entries, changes, deletions, and the identity of the person making changes with timestamps

EDC audit trails create an automatic, computer-generated, time-stamped record of all actions taken in the system, supporting data integrity and regulatory inspection readiness.

Question 61: A sponsor wishes to implement a protocol amendment that changes the primary endpoint. Which regulatory body must approve this amendment before it can be implemented at US sites?

Both the FDA (via IND amendment) and the IRB (Correct answer)
The FDA only
The IRB only
The DSMB and the sponsor's medical monitor

Correct answer: Both the FDA (via IND amendment) and the IRB

Significant protocol changes must be submitted to the FDA as an IND amendment and approved by the site's IRB before implementation.

Question 62: A source document verification (SDV) check reveals that a subject's weight recorded in the eCRF differs from the medical chart. What should the CRA do?

Accept the eCRF value as the official record
Notify the IRB of the data discrepancy
Request the investigator or designee issue a data query to reconcile the discrepancy (Correct answer)
Correct the eCRF entry directly

Correct answer: Request the investigator or designee issue a data query to reconcile the discrepancy

The CRA should raise a data query so that authorized site personnel can review source documents and correct the eCRF with appropriate audit trail documentation.

Question 63: What qualifies as a 'source document' in a clinical trial?

Original records and certified copies of original information including medical records, lab reports, and subject diaries (Correct answer)
Only the Case Report Form (CRF)
The protocol and amendments only
Electronic data capture system printouts only

Correct answer: Original records and certified copies of original information including medical records, lab reports, and subject diaries

Source documents are original records from which subject data are first captured, including hospital records, clinic charts, laboratory notes, diaries, pharmacy records, and imaging results.

Question 64: A 'certified copy' of a source document is acceptable when:

The original document has been destroyed
It is signed only by the CRA
It is created by the CRA during the monitoring visit
It is a verified copy that has been confirmed as an exact copy of the original through a documented process (Correct answer)

Correct answer: It is a verified copy that has been confirmed as an exact copy of the original through a documented process

A certified copy is a copy verified to be a true and accurate copy of the original through a documented certification process, and it may be retained in place of the original when needed.

Question 65: A 'SUSAR' stands for Suspected Unexpected Serious Adverse Reaction and must meet which THREE criteria?

Related, unexpected, and non-serious
Serious, unexpected, and possibly related to the investigational product (Correct answer)
Unexpected, life-threatening, and causing hospitalization only
Serious, severe, and occurring in more than one subject

Correct answer: Serious, unexpected, and possibly related to the investigational product

A SUSAR must be serious (meets seriousness criteria), unexpected (not in the IB), and have a reasonable suspected causal relationship to the investigational product.

Question 66: Which ICH E6(R2) principle requires that each individual involved in conducting a trial should be qualified by education, training, and experience?

Principle 3 — qualified personnel (Correct answer)
Principle 7 — confidentiality protection
Principle 2 — IRB oversight
Principle 12 — data integrity

Correct answer: Principle 3 — qualified personnel

ICH E6(R2) Principle 3 specifies that all trial personnel must be qualified by education, training, and experience to perform their tasks.

Question 67: A sponsor-CRA learns that an investigator has not reported a serious adverse event (SAE) to the IRB within the required timeframe. What must the CRA do?

Amend the protocol to remove the SAE reporting requirement
Report the SAE to the IRB directly on behalf of the investigator
Document the finding, notify the investigator of the obligation, and escalate to sponsor management per the monitoring plan (Correct answer)
Close the site immediately and notify the FDA

Correct answer: Document the finding, notify the investigator of the obligation, and escalate to sponsor management per the monitoring plan

The CRA must document the deviation, remind the investigator of their reporting obligation, and escalate to sponsor management as specified in the monitoring plan.

Question 68: Which document must be reviewed and filed in the Trial Master File (TMF) BEFORE initiating a clinical trial site?

Completed database lock confirmation
Final signed Clinical Study Report
Post-market surveillance report
IRB/IEC approval letter and approved informed consent form (Correct answer)

Correct answer: IRB/IEC approval letter and approved informed consent form

IRB/IEC approval of the protocol and informed consent form is a regulatory prerequisite that must be on file before any study activities commence at the site.

Question 69: Which of the following best describes a 'serious adverse event' (SAE) per ICH E2A?

Any adverse event that causes mild discomfort or requires dose reduction
Any expected side effect listed in the Investigator's Brochure
Any laboratory abnormality regardless of clinical significance
Any adverse event that results in death, is life-threatening, requires hospitalization, or causes persistent disability (Correct answer)

Correct answer: Any adverse event that results in death, is life-threatening, requires hospitalization, or causes persistent disability

An SAE is defined by ICH E2A as any adverse event that results in death, is life-threatening, requires inpatient hospitalization, causes persistent significant disability, or is a congenital anomaly.

Question 70: A subject who previously signed informed consent now lacks decision-making capacity due to an adverse event. Who may provide continued consent for their participation?

A legally authorized representative (LAR) as defined by applicable law (Correct answer)
The IRB must re-consent the subject at the next meeting
The principal investigator may waive further consent
The site coordinator may re-consent on the subject's behalf

Correct answer: A legally authorized representative (LAR) as defined by applicable law

When a subject loses capacity, a legally authorized representative defined by applicable law and IRB-approved procedures may provide surrogate consent.

Question 71: The Declaration of Helsinki, as it relates to clinical research, emphasizes that:

Subjects may be enrolled without consent if the research has societal benefit
The well-being of individual research subjects must take precedence over the interests of science and society (Correct answer)
Investigators are not required to disclose conflicts of interest
Placebo-controlled trials are always unethical when existing treatment is available

Correct answer: The well-being of individual research subjects must take precedence over the interests of science and society

The Declaration of Helsinki places the health and rights of individual subjects above scientific and societal interests, forming an ethical cornerstone of clinical research.

Question 72: During a Site Initiation Visit (SIV), which of the following is the CRA's MOST critical responsibility?

Reviewing all previously published literature on the investigational product
Ensuring all site staff are trained and documented on the protocol before enrollment begins (Correct answer)
Submitting the final Clinical Study Report to the IRB
Requesting a list of all patients who may be eligible for the study

Correct answer: Ensuring all site staff are trained and documented on the protocol before enrollment begins

The SIV ensures all site personnel are adequately trained and that training documentation is complete before the first subject is enrolled.

Question 73: Which of the following best describes the Trial Master File (TMF) in the context of site initiation?

A summary document generated only after study completion
A comprehensive collection of essential documents that individually and collectively permit evaluation of the conduct of a trial (Correct answer)
A database used exclusively by the FDA to evaluate clinical trials
A file containing only the financial agreements between sponsor and site

Correct answer: A comprehensive collection of essential documents that individually and collectively permit evaluation of the conduct of a trial

Per ICH E6, the TMF contains essential documents that allow reconstruction of trial conduct and is maintained by both the sponsor and investigator throughout the trial.

Question 74: A subject reports a new, unexpected, drug-related serious adverse event. According to ICH E6, within what timeframe must the investigator report this to the sponsor?

Within 24 hours of becoming aware (Correct answer)
Within 15 calendar days
Within 7 calendar days
Within 48 hours of becoming aware

Correct answer: Within 24 hours of becoming aware

ICH E6(R2) requires investigators to report all serious adverse events to the sponsor immediately, and no later than 24 hours of their becoming aware of the event.

Question 75: What is the purpose of a Data Safety Monitoring Board (DSMB) in a clinical trial?

To manage the randomization schedule for the sponsor
To independently monitor accumulating trial data and recommend stopping or modifying the trial if warranted (Correct answer)
To approve all protocol amendments before they are implemented
To perform source data verification at investigative sites

Correct answer: To independently monitor accumulating trial data and recommend stopping or modifying the trial if warranted

A DSMB is an independent committee that reviews accumulating efficacy and safety data and can recommend trial modifications or early termination to protect subjects.

Question 76: A sponsor is planning a multi-site trial across five countries. Which regulatory body's guidelines provide the internationally accepted standard for GCP that covers study design, conduct, performance, monitoring, and reporting?

ISO (International Organization for Standardization) through ISO 14155
CIOMS (Council for International Organizations of Medical Sciences)
WHO (World Health Organization) through its Model List of Essential Medicines
ICH (International Council for Harmonisation) through Guideline E6 (Correct answer)

Correct answer: ICH (International Council for Harmonisation) through Guideline E6

ICH E6 (Good Clinical Practice) is the internationally harmonized standard for the design, conduct, performance, monitoring, auditing, recording, analysis, and reporting of clinical trials.

Question 77: Under the ALCOA principles for data integrity in clinical trials, what does the 'A' stand for and why is it critical?

Anonymous — subject identifiers must be removed from all records
Audited — every record must be independently verified by the CRA
Automated — electronic systems must generate all entries
Accurate — data must reflect the true value measured, ensuring trial results are reliable (Correct answer)

Correct answer: Accurate — data must reflect the true value measured, ensuring trial results are reliable

ALCOA stands for Attributable, Legible, Contemporaneous, Original, and Accurate; 'Accurate' ensures recorded data reflects the true measurement, which is foundational to valid trial results.

Question 78: In the US, a sponsor must submit an IND application to the FDA before:

Publishing trial results
Shipping investigational drug to sites
Both B and C (Correct answer)
Initiating a Phase I clinical trial in humans

Correct answer: Both B and C

An IND must be submitted before shipping investigational drug and before initiating a clinical trial in human subjects in the United States.

Question 79: Which US regulation specifically governs Institutional Review Board (IRB) requirements for FDA-regulated clinical trials?

45 CFR Part 46
21 CFR Part 56 (Correct answer)
21 CFR Part 312
21 CFR Part 50

Correct answer: 21 CFR Part 56

21 CFR Part 56 sets forth the requirements for IRB composition, operations, and review of clinical investigations regulated by the FDA.

Question 80: A subject's source document shows a glucose value of 450 mg/dL, but the CRF records 45 mg/dL. How should this discrepancy be handled?

Ask the investigator to re-draw the sample to get a new value
Issue a data query to the site to correct the CRF entry with a documented explanation (Correct answer)
Accept the CRF value as the data was already entered
Correct the CRF using white-out and initial the change

Correct answer: Issue a data query to the site to correct the CRF entry with a documented explanation

Transcription errors between source documents and CRFs must be resolved through a formal data query so the correction is auditable.

Question 81: Which of the following best describes 'open-label' trial design with respect to investigational product management?

IP is provided with no label or identification
Both subjects and investigators know which treatment is being administered, with no blinding of treatment assignment (Correct answer)
Only the subject is unblinded while the investigator remains blinded
The IP label includes the subject's name publicly

Correct answer: Both subjects and investigators know which treatment is being administered, with no blinding of treatment assignment

In an open-label trial, there is no blinding — both the subject and the site staff know which treatment the subject is receiving, simplifying IP management but introducing potential bias.

Question 82: What is the regulatory requirement for corrections made to paper CRF data?

Draw a single line through the error, write the correct value, initial, and date the correction (Correct answer)
Delete the entire page and resubmit a clean CRF
Corrections must be made only by the CRA
Use white-out to remove the error and write the correct value

Correct answer: Draw a single line through the error, write the correct value, initial, and date the correction

GCP requires that CRF corrections preserve the original entry; the correct method is a single line through the error so the original is still legible, with the correction, date, and initials of the person making the change.

Question 83: What is the difference between an Adverse Event (AE) and an Adverse Drug Reaction (ADR)?

An ADR implies at least a possible causal relationship to the study drug, while an AE does not require causality (Correct answer)
An ADR applies only to marketed drugs, not investigational products
An AE requires hospitalization while an ADR does not
An AE is always more serious than an ADR

Correct answer: An ADR implies at least a possible causal relationship to the study drug, while an AE does not require causality

An AE is any untoward medical occurrence temporally associated with study drug use, regardless of causality; an ADR implies a causal relationship has been at least reasonably suspected.

Question 84: What is a 'protocol deviation' versus a 'protocol violation' in clinical research?

A violation is always intentional, while a deviation is always accidental
They are interchangeable terms with no meaningful distinction
A deviation is a minor, unplanned departure from the protocol; a violation is a more serious departure that may affect subject safety or data integrity (Correct answer)
A deviation requires FDA reporting; a violation does not

Correct answer: A deviation is a minor, unplanned departure from the protocol; a violation is a more serious departure that may affect subject safety or data integrity

Deviations are minor unplanned departures from the protocol, while violations are serious departures that may impact subject safety or data validity and require prompt reporting.

Question 85: When a CRA discovers that an investigator site has been enrolling subjects before IRB approval was obtained, what is the FIRST action to take?

Place the site on clinical hold immediately
Terminate the site's participation in the trial
Retrain the site staff on GCP requirements
Document the finding and notify the sponsor promptly (Correct answer)

Correct answer: Document the finding and notify the sponsor promptly

The CRA must document the protocol deviation and notify the sponsor promptly so that corrective actions can be evaluated and regulatory obligations met.

Question 86: Which organization administers the CCRA certification examination in the United States?

The National Institutes of Health (NIH)
The Society of Clinical Research Associates (SoCRA)
The FDA Office of Clinical Research
The Association of Clinical Research Professionals (ACRP) (Correct answer)

Correct answer: The Association of Clinical Research Professionals (ACRP)

ACRP (Association of Clinical Research Professionals) administers the CCRA certification exam and sets the competency standards for clinical research associates.

Question 87: The principle of 'equipoise' in clinical research ethics means:

Equal compensation for all participants
Equal randomization of subjects
Genuine uncertainty about which treatment is superior (Correct answer)
Balanced placebo-to-treatment ratio

Correct answer: Genuine uncertainty about which treatment is superior

Clinical equipoise refers to genuine uncertainty in the expert medical community about the comparative merits of treatments being studied, justifying the ethical conduct of a trial.

Question 88: According to 21 CFR Part 50, which of the following elements is REQUIRED to be included in an informed consent document?

A description of any reasonably foreseeable risks or discomforts (Correct answer)
A listing of all FDA-approved therapies for the condition
The investigator's salary for conducting the research
The names of all competing investigational products

Correct answer: A description of any reasonably foreseeable risks or discomforts

21 CFR 50.25 requires informed consent documents to describe reasonably foreseeable risks or discomforts to the subject.

Question 89: A 'data reconciliation' process between the safety database and the clinical database is performed to:

Reconcile laboratory values with imaging data
Match financial invoices with subject visit data
Confirm randomization assignments match enrollment logs
Ensure all adverse events captured in the safety system are accurately reflected in the clinical database and vice versa (Correct answer)

Correct answer: Ensure all adverse events captured in the safety system are accurately reflected in the clinical database and vice versa

Safety-to-clinical database reconciliation ensures that all adverse events, medications, and safety data are consistently recorded in both the safety reporting system and the clinical EDC.

Question 90: Which entity is responsible for assessing the causality (relatedness) of an adverse event to the investigational product?

The CRA during the monitoring visit
The subject or patient
The investigator, and separately the sponsor's medical monitor (Correct answer)
The IRB during the annual review

Correct answer: The investigator, and separately the sponsor's medical monitor

Both the investigator and the sponsor's medical monitor independently assess causality; both assessments must be documented and both can be required in regulatory reports.

Question 91: When a clinical trial uses an interactive response technology (IRT/IVRS/IWRS) system for randomization and IP management, the system's primary functions include:

Managing subject randomization, treatment assignment, and investigational product dispensing and resupply logistics (Correct answer)
Generating adverse event reports automatically
Submitting regulatory documents to the FDA
Tracking site monitoring visit schedules

Correct answer: Managing subject randomization, treatment assignment, and investigational product dispensing and resupply logistics

IRT systems (IVRS for voice, IWRS for web) are used to randomize subjects, assign treatment, manage IP kit assignment, and trigger resupply orders based on site inventory levels.

Question 92: What phase is the patient NOT healthy?

At phase 8
At phase 4
At phase 2 (Correct answer)
At phase 98

Correct answer: At phase 2

In clinical trials, Phase 1 studies typically involve a small group of healthy volunteers to assess drug safety and dosage. Phase 2 studies, however, involve a larger group of patients who actually have the condition the drug is intended to treat. Therefore, patients in Phase 2 are generally not healthy, as the drug's efficacy and further safety are being evaluated in the target population.

Question 93: Which regulation requires informed consent to be obtained in a language understandable to the subject?

ICH E6(R2) Section 4.8
21 CFR Part 56
21 CFR Part 50 (Correct answer)
45 CFR Part 46

Correct answer: 21 CFR Part 50

21 CFR Part 50 specifies that the information given to subjects must be in language understandable to the subject or their legally authorized representative.

Question 94: At a Site Closeout Visit (COV), which activity is MOST critical for the CRA to confirm?

The site's financial invoices are paid
Subject enrollment targets were met
Future trial opportunities are discussed with the investigator
All trial materials are accounted for and essential documents are complete and archived (Correct answer)

Correct answer: All trial materials are accounted for and essential documents are complete and archived

During closeout, the CRA must ensure all investigational product is reconciled, essential documents are complete, and the site understands retention requirements for regulatory inspection readiness.

Question 95: Which Belmont Report principle requires that the benefits of research be maximized and harms minimized?

Justice
Autonomy
Beneficence (Correct answer)
Respect for persons

Correct answer: Beneficence

The principle of beneficence obligates researchers to maximize possible benefits and minimize possible harms when conducting research with human subjects.

Question 96: Under ICH E6(R2), an investigator must report a serious adverse event to the sponsor:

At the next scheduled monitoring visit
Only if the event is considered related to the study drug
Immediately, typically within 24 hours of learning of the event (Correct answer)
Within 30 days of occurrence

Correct answer: Immediately, typically within 24 hours of learning of the event

ICH E6(R2) section 4.11.1 requires investigators to report SAEs to the sponsor immediately upon learning of the event, except for SAEs exempted in the protocol.

Question 97: Which regulatory guidance specifically supports a reduced and risk-adapted approach to source data verification?

21 CFR Part 50 Informed Consent
ICH E8 General Considerations for Clinical Studies
FDA Guidance on IND Applications (2012)
FDA Guidance for Industry: Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring (2013) (Correct answer)

Correct answer: FDA Guidance for Industry: Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring (2013)

The FDA's 2013 RBM guidance explicitly endorses a risk-based approach to monitoring including targeted SDV focused on critical data rather than 100% verification of all data.

Question 98: Who is authorized to dispense investigational product at a clinical trial site?

Any site staff member listed on the trial team list
Any licensed pharmacist regardless of trial training
Only qualified personnel delegated and documented on the Delegation of Authority Log, typically the pharmacist or designated nurse/coordinator (Correct answer)
The CRA during monitoring visits

Correct answer: Only qualified personnel delegated and documented on the Delegation of Authority Log, typically the pharmacist or designated nurse/coordinator

Only personnel specifically trained and authorized on the site's Delegation of Authority Log may dispense IP; this typically requires trial-specific training and pharmacy or nursing qualifications.

Question 99: Which document formally authorizes a site to begin receiving and storing investigational product?

The CRA's monitoring plan
The Site Initiation Visit report
A confirmed IRB approval letter, signed protocol, and completed 1572, with sponsor confirmation of site activation (Correct answer)
The Clinical Trial Agreement (financial contract)

Correct answer: A confirmed IRB approval letter, signed protocol, and completed 1572, with sponsor confirmation of site activation

A site must have all regulatory and contractual requirements in place — including IRB approval, signed protocol and 1572, and sponsor activation confirmation — before IP can be shipped or dispensed.

Question 100: Subject medication compliance (adherence) is most commonly assessed in clinical trials by:

Investigator opinion during clinic visits
Sponsor review of financial payment records
Pill/device counts, subject diaries, or plasma drug level measurements (Correct answer)
Subject self-report at final visit only

Correct answer: Pill/device counts, subject diaries, or plasma drug level measurements

Compliance is typically measured through returned pill counts, patient diary records of doses taken, and/or pharmacokinetic sampling to confirm drug exposure, as specified in the protocol.

Question 101: During a monitoring visit, a CRA notices the Delegation of Authority Log does not include a recently added sub-investigator. The BEST action is to:

Require the PI to update the log before the sub-investigator performs any further trial-related activities (Correct answer)
Submit a protocol deviation on behalf of the site
Remove the sub-investigator from all future trial activities
Perform the visit as planned and note it as a non-issue

Correct answer: Require the PI to update the log before the sub-investigator performs any further trial-related activities

All personnel performing trial-related duties must be listed on the Delegation of Authority Log; the PI must update it immediately to maintain GCP compliance before the sub-investigator continues trial activities.

Question 102: What is the role of the Data Safety Monitoring Board (DSMB) in a clinical trial?

To approve the protocol before the trial begins
To independently review accumulating safety and efficacy data and recommend continuation, modification, or termination of the trial (Correct answer)
To manage the randomization schedule for subjects
To conduct site inspections on behalf of the FDA

Correct answer: To independently review accumulating safety and efficacy data and recommend continuation, modification, or termination of the trial

A DSMB is an independent committee that periodically reviews unblinded data to protect the safety of trial participants and the validity of the trial.

Question 103: What is the role of a Central IRB (cIRB) in a multi-site clinical trial?

To provide a single ethics review that can cover multiple sites, streamlining oversight (Correct answer)
To replace the FDA as the primary regulatory reviewer
To adjudicate disputes between investigators and the sponsor
To monitor site compliance with the protocol on behalf of the sponsor

Correct answer: To provide a single ethics review that can cover multiple sites, streamlining oversight

A central IRB conducts a single ethics review applicable to multiple participating sites, reducing duplication and streamlining the approval process.

Question 104: What percentage of SDV is typically used in a traditional 100% SDV monitoring approach?

10% random sampling of all data
100% of all CRF data compared to source documents (Correct answer)
25% of critical data fields
50% of safety data only

Correct answer: 100% of all CRF data compared to source documents

Traditional monitoring required 100% SDV of all CRF data against source documents, though modern risk-based approaches allow reduced SDV targeting critical data only.

Question 105: Which element is NOT required to be included in an informed consent form according to 21 CFR Part 50.25?

The subject's social security number (Correct answer)
A description of foreseeable risks or discomforts
A statement that participation is voluntary
The expected duration of the subject's participation

Correct answer: The subject's social security number

21 CFR 50.25 lists required ICF elements, and a subject's social security number is not among them; collecting it would be a privacy concern.

Question 106: Who is present when a SIV occurs?

During a SIV the PI, Sub I, SC, and other key staff are present. (Correct answer)
Clinical research organization
Any untoward event that may or may not be related to the study drug that was not originally identified within the subjects medical history
Oncology, Cardiology, General Medicine

Correct answer: During a SIV the PI, Sub I, SC, and other key staff are present.

A Site Initiation Visit (SIV) is a crucial meeting held before a clinical trial begins patient enrollment. During an SIV, the Principal Investigator (PI), Sub-Investigators (Sub I), Study Coordinator (SC), and other key site staff involved in the trial are present. This ensures that all personnel understand the protocol, their roles, regulatory requirements, and study procedures.

Question 107: A 'Certificate of Analysis' (CoA) for investigational product is used primarily to verify:

Subject eligibility criteria
Site staff qualifications
Drug identity, purity, potency, and quality (Correct answer)
IRB approval dates

Correct answer: Drug identity, purity, potency, and quality

A CoA documents that the investigational product meets specified quality attributes including identity, purity, potency, and other release specifications.

Question 108: An IP 'expiry date extension' means:

The site can continue using expired IP if no new supplies are available
The sponsor has performed additional stability testing and obtained regulatory approval to extend the product's use-by date (Correct answer)
The protocol enrollment period has been extended
The IRB has approved additional drug use beyond the original period

Correct answer: The sponsor has performed additional stability testing and obtained regulatory approval to extend the product's use-by date

Expiry extensions require new stability data demonstrating the product remains within specifications, followed by updated labeling and regulatory notification where required.

Question 109: Which ICH-GCP guideline governs the conduct of clinical trials to ensure data integrity and subject safety?

ICH E3
ICH E6(R2) (Correct answer)
ICH E8
ICH E9

Correct answer: ICH E6(R2)

ICH E6(R2) is the Good Clinical Practice guideline that establishes international standards for designing, conducting, recording, and reporting trials involving human subjects.

Question 110: A 'data management plan' (DMP) in a clinical trial typically includes:

Investigational product manufacturing specifications
The statistical analysis plan for primary endpoints only
Database design, data collection procedures, validation rules, and quality control processes for the trial's data (Correct answer)
Subject recruitment and retention strategies

Correct answer: Database design, data collection procedures, validation rules, and quality control processes for the trial's data

The DMP outlines how data will be collected, validated, cleaned, and managed throughout the trial, covering EDC configuration, query management, coding, and database lock procedures.

Question 111: A 'trigger' in risk-based monitoring refers to:

The activation of the randomization system
The date the site submits the first CRF page
The signal that prompts an unplanned site visit or escalated review based on predefined thresholds (Correct answer)
A sponsor instruction to increase enrollment pace

Correct answer: The signal that prompts an unplanned site visit or escalated review based on predefined thresholds

Triggers are predefined thresholds or signals (e.g., high query rate, low consent rate) that prompt escalated monitoring actions such as additional on-site or centralized review.

Question 112: During a monitoring visit, a CRA finds a discrepancy between the CRF and source data. The FIRST action should be:

Correct the CRF entry directly
Remove the subject from the dataset
Immediately report to the FDA
Request a query be raised and ask site staff to correct the CRF with explanation (Correct answer)

Correct answer: Request a query be raised and ask site staff to correct the CRF with explanation

Discrepancies should be resolved through the formal query process so that any CRF corrections are made by authorized site staff with appropriate documentation and explanation.

Question 113: In electronic clinical trials, 21 CFR Part 11 governs:

The use of electronic records and electronic signatures, ensuring they are trustworthy and equivalent to paper records (Correct answer)
The clinical pharmacology requirements for investigational drugs
The IRB review process for online-recruited subjects
The format of IND application submissions

Correct answer: The use of electronic records and electronic signatures, ensuring they are trustworthy and equivalent to paper records

21 CFR Part 11 establishes FDA requirements for electronic records and signatures to be considered reliable, trustworthy, and equivalent to their paper counterparts, covering audit trails, access controls, and validation.

Question 114: A subject experiences a Serious Adverse Event (SAE) on a Monday. Within what timeframe must the investigator report an unexpected, fatal SAE to the sponsor under ICH E6(R2)?

Within 30 calendar days
Within 24 hours
Within 7 calendar days (Correct answer)
Within 15 business days

Correct answer: Within 7 calendar days

ICH E6(R2) requires investigators to report fatal or life-threatening unexpected SAEs to the sponsor within 7 calendar days of first awareness.

Question 115: Subject diaries used to collect patient-reported outcomes (PROs) are considered:

Secondary data derived from clinical assessments
Not admissible as evidence in regulatory submissions
Source documents, as they represent the original record of subject-reported information (Correct answer)
CRF data only, not source data

Correct answer: Source documents, as they represent the original record of subject-reported information

Subject diaries are source documents because they capture data directly from the subject as the original record, and must be retained according to the same archiving requirements as other source documents.

Question 116: Source Data Verification (SDV) involves comparing CRF data to:

The investigator brochure
The monitoring report
The protocol
Original source documents such as medical records and lab reports (Correct answer)

Correct answer: Original source documents such as medical records and lab reports

SDV is the process of comparing data recorded in the CRF or EDC system against the original source documents to confirm accuracy, completeness, and consistency.

Question 117: If a site's pharmacy refrigerator storing investigational product fails overnight, the CRA should advise the site to:

Document the excursion details (temperature range, duration) and contact the sponsor's clinical supply team for disposition guidance before dispensing affected product (Correct answer)
Immediately discard all affected IP without notifying the sponsor
Replace the IP from their own supply
Continue dispensing the product since one night is unlikely to matter

Correct answer: Document the excursion details (temperature range, duration) and contact the sponsor's clinical supply team for disposition guidance before dispensing affected product

Temperature excursions must be fully documented and assessed by the sponsor's supply and quality teams before any affected product is used; dispensing compromised IP could harm subjects.

Question 118: When EDC is used as the source of truth and data are entered directly into the EDC system without prior paper records, these data are called:

Derived data
eSource data (Correct answer)
Transferred data
Secondary data

Correct answer: eSource data

eSource refers to clinical trial data captured directly in electronic systems (e.g., EDC, EHR) as the original source, without an intermediate paper record being created.

Question 119: What does the term 'source document verification (SDV)' refer to in clinical monitoring?

Checking that the protocol has been approved by the IRB
Verifying the identity of the investigator at the site
Comparing CRF data to original source documents to confirm accuracy (Correct answer)
Creating electronic copies of paper records

Correct answer: Comparing CRF data to original source documents to confirm accuracy

SDV is the process of comparing data recorded in the CRF against original source documents to ensure data accuracy and integrity.

Question 120: The 'randomization code' in a blinded clinical trial is maintained to:

Reduce the number of placebo-assigned subjects
Ensure balanced age distribution across treatment arms
Enable emergency unblinding for subject safety and final unblinding for statistical analysis (Correct answer)
Allow site coordinators to optimize treatment allocation

Correct answer: Enable emergency unblinding for subject safety and final unblinding for statistical analysis

Randomization codes are securely maintained so they can be accessed in emergencies (e.g., to determine treatment for safety management) and at study end for statistical analysis.

Question 121: ICH E6(R2) defines 'essential documents' as those that individually and collectively permit evaluation of the conduct of a trial and:

The financial costs incurred
The publication timeline
The site selection criteria
The quality of the data produced (Correct answer)

Correct answer: The quality of the data produced

Essential documents allow evaluation of both the conduct of the trial and the quality of data generated, and are required to be maintained throughout and after the trial.

Question 122: A 'temperature excursion' for investigational product occurs when:

IP storage conditions deviate outside the protocol-specified temperature range (Correct answer)
The IP is shipped to an unapproved country
The IP dispensing log shows missing entries
The IP expiration date passes without disposal

Correct answer: IP storage conditions deviate outside the protocol-specified temperature range

A temperature excursion is when IP is exposed to temperatures outside the specified storage range; the sponsor's medical/quality team must evaluate whether the affected IP remains usable.

Question 123: When must a protocol deviation be reported to the IRB according to standard GCP practice?

All deviations must be reported within 24 hours
Deviations are only reported at study close-out
Only deviations that affect subject safety or data integrity require IRB reporting per IRB SOPs (Correct answer)
Deviations are never reported to the IRB, only to the sponsor

Correct answer: Only deviations that affect subject safety or data integrity require IRB reporting per IRB SOPs

IRB reporting requirements vary by institution, but deviations that affect subject safety, rights, or data integrity generally require prompt IRB notification per site SOPs.

Question 124: The 'data lock' in a clinical trial refers to:

The point at which the database is closed to further changes in preparation for statistical analysis (Correct answer)
Locking physical CRF binders at the site
Encrypting the trial database at study startup
The EDC system going offline for maintenance

Correct answer: The point at which the database is closed to further changes in preparation for statistical analysis

Database lock is the formal process of freezing the clinical database after all data queries are resolved, confirming the dataset is complete and ready for unblinded statistical analysis.

Question 125: Under GCP, what does the term 'blinding/masking' refer to in the context of a randomized controlled trial?

Restricting subject access to their own medical records
Concealing the study protocol from regulators
Destroying unneeded study documents after trial completion
Preventing one or more parties from knowing the treatment assignment (Correct answer)

Correct answer: Preventing one or more parties from knowing the treatment assignment

Blinding prevents knowledge of treatment assignment by subjects, investigators, or both to reduce bias in a randomized controlled trial.

CCRA® — Certified Clinical Research Associate

The CCRA® credential, offered by ACRP, validates the knowledge and skills of clinical research associates who monitor clinical trials to ensure GCP compliance, participant safety, data integrity, and regulatory adherence across all phases of drug and device development.

125

Questions

180 min

Time Limit

70%

To Pass

Checking for saved progress...

Exam Rules

You can skip questions and return to them later
Flag questions for review before submitting
No feedback shown until you submit the entire exam
Unanswered questions count as wrong — answer everything
10 pretest questions are mixed in and don't affect your score
Timer auto-submits when time runs out
Your progress is auto-saved every 30 seconds

These practice questions were written with AI tools. They are not real exam questions. Exam facts are checked against the official sources listed below. Not reviewed by a subject-matter expert. Editorial policy

Sources & references

Exam facts on this page (fees, format, dates, passing scores) are checked against these official sources; the date is our last check. Editorial policy

acrpnet.org — Registration deadline, eligibility, fees, exam format, score release, test dates, time limit, score validity, registration, retake fee · verified Nov 2026
test-takers.psiexams.com — Test delivery · verified Oct 2026